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ORIGINAL ARTICLE
Disease-associated polymorphisms in ERAP1 do not alter
endoplasmic reticulum stress in patients with ankylosing
spondylitis
TJ Kenna1, MC Lau1, P Keith1, F Ciccia2, M-E Costello1, L Bradbury1, P-L Low1, N Agrawal1, G Triolo2, R Alessandro2, PC Robinson1,
GP Thomas1 and MA Brown1
The mechanism by which human leukocyte antigen B27 (HLA-B27) contributes to ankylosing spondylitis (AS) remains unclear.
Genetic studies demonstrate that association with and interaction between polymorphisms of endoplasmic reticulum
aminopeptidase 1 (ERAP1) and HLA-B27 inﬂuence the risk of AS. It has been hypothesised that ERAP1-mediated HLA-B27 misfolding
increases endoplasmic reticulum (ER) stress, driving an interleukin (IL) 23-dependent, pro-inﬂammatory immune response.
We tested the hypothesis that AS-risk ERAP1 variants increase ER-stress and concomitant pro-inﬂammatory cytokine production in
HLA-B27+ but not HLA-B27− AS patients or controls. Forty-nine AS cases and 22 healthy controls were grouped according to HLA-B27
status and AS-associated ERAP1 rs30187 genotypes: HLA-B27+ERAP1risk, HLA-B27+ERAP1protective, HLA-B27−ERAP1risk and HLA-
B27−ERAP1protective. Expression levels of ER-stress markers GRP78 (8 kDa glucose-regulated protein), CHOP (C/EBP-homologous protein)
and inﬂammatory cytokines were determined in peripheral blood mononuclear cell and ileal biopsies. We found no differences in
ER-stress gene expression between HLA-B27+ and HLA-B27− cases or healthy controls, or between cases or controls stratiﬁed by
carriage of ERAP1 risk or protective alleles in the presence or absence of HLA-B27. No differences were observed between
expression of IL17A or TNF (tumour necrosis factor) in HLA-B27+ERAP1risk, HLA-B27+ERAP1protective and HLA-B27−ERAP1protective cases.
These data demonstrate that aberrant ERAP1 activity and HLA-B27 carriage does not alter ER-stress levels in AS, suggesting that
ERAP1 and HLA-B27 may inﬂuence disease susceptibility through other mechanisms.
Genes and Immunity advance online publication, 6 November 2014; doi:10.1038/gene.2014.62
INTRODUCTION
Susceptibility to ankylosing spondylitis (AS), the prototypic
spondyloarthropathy, is largely genetically determined, with the
heritability of disease risk estimated at 490%.1 The endoplasmic
reticulum aminopeptidase 1 (ERAP1) gene is strongly associated
with AS; only the class I major histocompatibility complex allele,
HLA-B27 (human leukocyte antigen B27) shows stronger
association.2 ERAP1 (formerly known as ARTS-1) is an aminopepti-
dase with a ubiquitous tissue distribution, which is expressed in
the endoplasmic reticulum (ER). ERAP1 has two reported
functions. First, in vitro studies have suggested that ERAP1 may
function as a 'sheddase', cleaving cytokine receptors off the cell
surface, including interleukin-6 receptor subunit alpha (IL-6R),
interleukin-1 receptor type 2 (IL-1R2) and tumour necrosis factor
receptor (TNF-R), each of which are encoded by genes associated
with AS.3–6 However, we have demonstrated that spleen cells from
ERAP− /− mice did not show altered cleavage of IL-6R and TNF-R
in vitro.2 Moreover, in the context of AS, Haroon et al.7
demonstrated that ERAP1 polymorphisms do not alter serum
levels of inﬂammatory cytokines. Second, ERAP1 has been shown
to act as a ‘molecular ruler’, trimming peptides that have been
partially processed in the proteasome to the optimal length for
presentation on major histocompatibility complex class I
molecules.8 Polymorphisms in ERAP1 inﬂuence the quality and
quantity of major histocompatibility complex class I complexes
assembled and presented on the cell surface.9,10
Considering the imputed and genotyped data across ERAP1,
association with AS is most strongly localised to a block of single
nucleotide polymorphisms (SNPs) lying in a 4.6 kb region between
rs27529 (in exon 9) and rs469758 (in intron 12).2,11 In this region,
the only common (minor allele frequency 41%) coding
polymorphisms are rs30187 (Arg528Lys) and rs10050860
(Asp575Asn),12 and ﬁne-mapping and haplotype evolutionary
studies suggest that rs30187 is directly disease associated, and
that a second haplotype, tagged by rs10050860, is also AS
associated.2 We previously reported an interaction between ERAP1
and the major HLA class I alleles associated with AS, with
association of ERAP1 polymorphisms with AS being restricted to
HLA-B27-positive cases.2 In ERAP1, the Arg528Lys substitution
encoded by the protective SNP rs30187 causes a signiﬁcant
reduction in aminopeptidase activity towards a synthetic peptide
substrate when compared with the wild type, resulting in a two- to
threefold decrease in substrate afﬁnity.2 This is consistent with the
structural data demonstrating that Lys528Arg disease-protective
variants prevent the closed conformation of the protein catalytic
site,2 thereby leading to loss of ERAP1 function, though the exact
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mechanism of how this might contribute to AS pathogenesis
remains unclear.
Despite the association between HLA-B27 and AS being known
for almost 40 years, how HLA-B27 participates in AS pathogenesis
is still unresolved. Leading theories include the arthritogenic
peptide theory,13 and two theories involving non-canonical
properties of HLA-B27, the unfolded protein response (UPR) and
HLA-B27 homodimer formation.5 Compared with other HLA
molecules, HLA-B27 is slow to fold and associate with β2-
microglobulin.14 The UPR hypothesis postulates that the slow
rate of HLA-B27 folding triggers an intracellular signalling cascade
in the ER, which, in macrophages, stimulates production and
secretion of interleukin 23 (IL23). Evidence in support of the UPR
hypothesis is strongest in the HLA-B27-transgenic rat model, 15 but
has also been reported in the synovium of AS patients.16
ER stress, buffered by the activation of the UPR, is a homeostatic
signalling network that orchestrates the restoration of ER
function.17 UPR activation leads to upregulation of expression of
pro-inﬂammatory cytokines, such as TNF, IL17 and IL23, which are
also known to be pathogenic in AS. Studies in the HLA-B27-
transgenic rat model have implicated the association of HLA-B27
misfolding and ER-stress-dependent activation of UPR in spondy-
loarthritis. Bone marrow-derived macrophages sampled from
colon tissue from rats with inﬂammatory arthritis were demon-
strated to exhibit ER stress in the form of upregulated, UPR-
inducing levels of the transcription factor gene X-box-binding
protein 1 (XBP-1). Furthermore, the production of IL23 was
enhanced in colonic tissue.15 Unlike in human AS though, where
patients can have at most two copies of HLA-B27, in the HLA-B27-
transgenic rat model, multiple copies of the transgene are
required for arthritis to develop.18
To directly assess the role of ERAP1 in AS-attributed ER stress,
we examined the gene expression of ER-stress markers 78 kDa
glucose-regulated protein (GRP78) and C/EBP-homologous protein
(CHOP) using quantitative polymerase chain reaction (qPCR), and
correlated their levels with pro-inﬂammatory cytokine expression
levels in AS patients.
RESULTS AND DISCUSSION
The AS-risk associated rs30187 allele of ERAP1 does not lead to
altered levels of ER stress
Accumulation of unfolded proteins in the ER initiates stress
responses. The ER-resident chaperone GRP78 (GRP78/BiP) is
sequestered which then allows the activation of three main
effector molecules: activating transcription factor 6, serine/
threonine-protein kinase/endoribonuclease IRE1 and PRKR-like
ER kinase (PERK).19 One arm of this pathway involves the
activation of CHOP by PRKR-like ER kinase, ultimately resulting
in the upregulation of pro-inﬂammatory cytokines such as IL23.9
To assess whether AS-associated ERAP1 variants alter levels of ER
stress, we compared the relative expression of ER-stress genes
GRP78 and CHOP in peripheral blood mononuclear cells (PBMCs)
from patients carrying either the risk or protective allele of
rs30187. Gene expression was normalised to the expression
of the constitutive ribosomal gene RPL32. There were
no differences in the relative expression levels (ΔCT) of
GRP78 or CHOP between AS HLA-B27+rs30187risk (GRP78: ΔCT =
0.009 ± 0.001; CHOP: ΔCT = 0.024 ± 0.006; mean± s.e.m.), HLA-
B27+rs30187protective (GRP78: ΔCT = 0.007 ± 0.006; CHOP: ΔCT =
0.024 ± 0.002) and HLA-B27−rs30187protective individuals (GRP78:
ΔCT = 0.009 ± 0.001; CHOP: ΔCT = 0.022 ± 0.008; Figures 1a and b).
Excluding patients on TNF inhibitors and only studying those that
were anti-TNF naive did not alter the ﬁndings (data not shown).
Interferon gamma (IFN-γ) exposure is an important contributor
to ER stress in HLA-B27-expressing PBMC.20 To determine whether
ERAP1 variants alter HLA-B27 misfolding and ER stress, we
cultured PBMC from HLA-B27+ AS cases in the presence or
absence of IFN-γ using conditions described previously.15 After
24 h co-culture with IFN-γ all samples showed elevated expression
of GRP78 but not CHOP (Figure 1e). However, no differences were
seen in the ER-stress signature between HLA-B27+ cases carrying
either rs30187risk or rs30187protective alleles (Figures 1c and d).
ER stress is not different between HLA-B27+ and HLA-B27− AS
patients
To assess ER stress in AS patients independent of ERAP1 genotype,
we compared GRP78 and CHOP gene expression in HLA-B27+ and
HLA-B27− cases without stratiﬁcation by ERAP1 genotype. GRP78
and CHOP levels are not signiﬁcantly higher in AS HLA-B27+
patients, with either the rs30187 risk or protective allele of ERAP1,
than those who are not carriers of the allele (GRP78: P= 0.32;
CHOP: P= 1.0; Figures 1c and d). Therefore, differences in ER stress
are not observed in PBMC samples from AS cases carrying the
HLA-B27 allele compared with samples from HLA-B27-negative
cases (Figures 1e and f).
To test the possibility that the ER-stress signature observed
in AS patients has been saturated by ongoing inﬂammation,
we examined ER-stress gene expression in HLA-B27+ or
HLA-B27- healthy controls HLA-B27+rs30187risk (GRP78: ΔCT =
0.007 ± 0.001; CHOP: ΔCT = 0.023 ± 0.003; mean± s.e.m.), HLA-
B27+rs30187protective (GRP78: ΔCT = 0.010 ± 0.001; CHOP: ΔCT =
0.012 ± 0.003) and HLA-B27−rs30187protective individuals (GRP78:
ΔCT = 0.012 ± 0.007; CHOP: ΔCT = 0.024 ± 0.008). Similar levels of
GRP78 and CHOP gene expression were seen in controls (Figures
1g and h) as that was seen in AS patients (Figures 1a and b).
Pro-inﬂammatory cytokine gene expression is unaffected by
ERAP1 variants
Because inﬂammatory cytokines TNF, IL23 and IL17 are associated
with AS pathogenesis, we examined whether carriers of the
rs30187-risk allele would display elevated levels of TNF and IL17.
Both TNF and IL17 gene expression levels in PBMC were not
different between AS patients who were HLA-B27+rs30187risk (TNF:
ΔCT = 0.002 ± 0.001; IL17A: ΔCT = 1.4x10
− 6 ± 8.3 × 10− 7; IL23: ΔCT =
0.014 ± 0.004), HLA-B27+rs30187protective (TNF: ΔCT = 0.002 ± 0.001;
IL17A: ΔCT = 7.91x10
− 7 ± 1.52x10− 7; IL23: ΔCT = 0.025 ± 0.009) and
HLA-B27−rs30187protective (TNF: ΔCT = 0.002 ± 0.001; IL17A: ΔCT =
2.5x10− 6 ± 2.0x10− 6; IL23: ΔCT = 0.016 ± 0.006; Figure 2).
Serum levels of pro-inﬂammatory cytokines were independent of
ERAP1 genotype
To conﬁrm that the lack of association of ERAP1 genotype
with inﬂammatory cytokine gene expression corresponded
with a similar lack of association at the protein level, we
measured serum concentrations of disease-relevant cytokines in
HLA-B27+ patients with ERAP1-risk and protective alleles. Serum
was analysed only from anti-TNF therapy naive patients, not
receiving corticosteroids, at their ﬁrst presentation at our AS
specialist clinic. In total, serum cytokines were measured in 11
HLA-B27+rs30187risk and 20 HLA-B27+rs30187protective patients.
ERAP1 genotype did not alter serum expression of either TNF-α
(HLA-B27+rs30187risk: 12.46±17.03 pgml−1, HLA-B27+rs30187protective:
19.34±29.61 pgml−1) or IL17 (HLA-B27+rs30187risk: 2.45±7.22 pg-
ml−1, HLA-B27+rs30187protective: 4.23 ± 7.22 pgml− 1; P4 0.05 in
all cases; Figure 3).
Gene expression of markers of ER stress did not correlate with
disease severity
Having observed no differences in ER-stress and cytokine gene
expression between subjects with risk or protective ERAP1 alleles,
we investigated the correlation between measures of ER stress
and disease activity in AS patients. For HLA-B27+ individuals with
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Figure 1. GRP78 and CHOP gene expression is not altered by HLA-B27 status or ERAP1 genotype. qRT–PCR was used to determine the level of
GRP78 (a and c) and CHOP (b and d) gene expression from active AS patients (n= 49). AS patients carrying the rs30187-risk allele of ERAP1 and
those with the protective allele of ERAP1 rs30187 showed no signiﬁcant difference in GRP78 (a) or CHOP (b) gene expression. ERAP1 genotype
also did not alter ER-stress response to IFN-γ stimulation as measured by either GRP78 (c) or CHOP (d) gene expression. Furthermore, there was
no difference in either GRP78 (e) or CHOP (f) gene expression between HLA-B27+ and HLA-B27- patients irrespective of ERAP1 genotype
(P40.5 in all comparisons). Similar levels of ER-stress gene expression were seen in patient and control samples (g and h).
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AS, no correlation was observed between GRP78 expression and
erythrocyte sedimentation rate (R2 = 0.05, P= 0.14), C-reactive
protein (R2 = 0.0005, P= 0.91) or Bath Ankylosing Spondylitis
Disease Activity Index scores (R2 = 0.005, P= 0.66; Figures 4a–c).
Similarly, no correlation was observed between CHOP expression
and erythrocyte sedimentation rate (R2 = 0.056, P= 0.14), C-reac-
tive protein (R2 = 0.0005, P= 0.90) or Bath Ankylosing Spondylitis
Disease scores (R2 = 0.00005, P= 0.98). Thus, disease activity
appears to operate independently of ER stress. Because ER stress
activates the UPR, which is implicated in the production of
pro-inﬂammatory cytokines, correlations between expression of
ER-stress markers and that of TNF and IL17 were assessed. GRP78
and CHOP expression showed no linear relationship with
expression of either TNF (GRP78: R2 = 0.043, P= 0.19; CHOP:
R2 = 0.084, P= 0.06) or IL17 (GRP78: R2 = 0.016, P= 0.44; CHOP:
R2 = 0.004, P= 0.88; Figure 4). This indicates that ER stress is
unlikely to enhance the production of pro-inﬂammatory cytokines
in HLA-B27+ AS patient PBMC.
ER-stress signature in the gut is not altered by ERAP1 genotype
21 HLA-B27+ patients used for analysis of ER stress in the gut were
genotyped using TaqMan probes (Applied Biosystems, Mulgrave,
VIC, Australia) for a single-coding-region SNP rs30187 in the ERAP1
gene (Supplementary Material); 5 cases were homozygous for
the protective ‘G’ allele, 11 cases were heterozygous and 5 cases
were homozygous for the risk ‘A’ allele. ER-stress measures
were investigated in terminal ileal biopsies from these patients.
Gene expression of GRP78 was not altered in the gut by ERAP1
genotype (Figure 5a). Similarly, XBP-1 splicing, as determined by
examining the ratio of spliced:unspliced XBP-1, was not affected
by ERAP1 genotype in the gut of AS patients (Figure 5b). The
protein levels of GRP78 and XBP-1 were also evaluated by
immunohistochemistry. No signiﬁcant differential expression of
GRP78 or XBP-1 was observed in AS with risk or protective alleles
of ERAP1 (Figures 5c and d).
The forces driving the inﬂammation underlying immune-
mediated diseases such as AS remain elusive. Compelling genetic
data point to a strong role for antigen presentation in AS but how
this altered or aberrant antigen presentation affects disease is still
unclear.21 It has been recognised for several years that, relative to
other HLA molecules, HLA-B27 is slow to fold and assemble into a
functional HLA:peptide complex.14 Studies in the HLA-B27-
transgenic rat model of spondyloarthritis have indicated that
HLA-B27 misfolding invokes a UPR15 that can drive IL23
production by macrophages.9 The HLA-B27-transgenic rat model
also suggests a role for HLA-B27 independent of antigen
presentation in this model, since depletion of CD8 T cells had
no effect on disease development in this model.22 Polymorphisms
in those ERAP1 alleles associated with AS encode protein
differences that lead to altered rates of ERAP1 enzyme activity.2
Furthermore, we have demonstrated gene–gene interaction
between ERAP1 and HLA-B27 in AS.2 Altered rates of ERAP1
activity may therefore affect the rate at which HLA-B27:peptide
complexes fold in the ER which may, in turn, increase the levels of
UPR-derived inﬂammatory cytokines that are secreted by macro-
phages. To date, this has not been examined in AS patients. In this
study, we investigated the effects of the risk allele rs30187 of
ERAP1 on ER stress in AS. Our human data show, for the ﬁrst time,
that ER stress is not different in either PBMC or terminal ileal
biopsies from AS cases either positive or negative for HLA-B27, or
carrying AS risk or protective ERAP1 genotypes. Nor did we
observe ERAP1-modiﬁed responses to in vitro challenge with UPR-
inducing IFN-γ.
Figure 2. Inﬂammatory cytokine gene expression is not altered by ERAP1 genotype. Expression of TNF (a), IL17 (b) and IL23 (c) were
determined by qRT–PCR. The relative expression of these genes did not differ between AS patients carrying the ERAP1 rs30187 risk or
protective allele in either HLA-B27+ or HLA-B27− individuals (P40.5 in all comparisons).
Figure 3. Serum levels of IL17 and TNF. Serum was collected from 11 HLA-B27+ERAP1Risk and 20 HLA-B27+Protective AS patients not receiving
biologic or corticosteroid therapy. IL17 and TNF protein levels were determined in these samples by ELISA. No differences were seen in either
IL17 (a) or TNF (b) between patients with risk or protective ERAP1 genotypes (P40.05 for all comparisons).
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In the HLA-B27 transgenic rat model, bone marrow-derived
macrophages displaying increased levels of ER stress also secrete
elevated levels of IL23, providing a plausible mechanism for
induction of IL17-mediated autoinﬂammatory events in this
model.15 However, in AS patients we show there is no difference
in the gene expression of ER-stress markers or pro-inﬂammatory
cytokines between individuals carrying the HLA-B27 allele
irrespective of rs30187 status. Previous studies examining ER
stress and the UPR in HLA-B27+ or HLA-B27− AS patients
compared with controls similarly found no difference in ER stress
between these groups23,24 but this study failed to investigate the
effects of altered ERAP1 expression on ER-stress signatures.
A lack of support for ER-stress modulation in AS by either HLA-
B27 or ERAP1 is suggested in this study. That said, these ﬁndings
are underpowered for HLA-B27− individuals due to the small
number of HLA-B27- samples available to us for this study. In
addition, whether PBMC or terminal ileal biopsies isolated from AS
patients are the most appropriate target cells for examining ER
stress remains uncertain, but these tissues are the only readily
accessible disease-relevant tissues in AS patients. Lack of
involvement of the UPR in blood samples from AS has been
suggested in other studies,23 but our examination of disease-
relevant gut biopsies indicates that even in sites of high cellular
turnover and likely inﬂammation in AS patients ER-stress
responses are still not upregulated.
Our data show that ERAP1 genotype does not alter expression
of ER-stress genes in human PBMCs or terminal ileal biopsies of
gut samples. Furthermore, ER-stress gene expression levels are not
different between HLA-B27+ and HLA-B27− patients. Together
these data suggest that the mechanism of action of HLA-B27 and
ERAP1 in AS patients is independent of ER-stress induction. This
conclusion is further supported by the lack of correlation seen
between clinical measures of disease (erythrocyte sedimentation
rate, C-reactive protein and Bath Ankylosing Spondylitis
Disease Activity Index) and expression of ER-stress genes. Instead,
HLA-B27 may be pathogenic through formation of cell-surface
homodimers, which are recognised by auto-reactive T cells,
including KIR3DL2+ CD4 T cells.25 Altered ERAP1 function may
result in cell-surface presentation of aberrant HLA-B27:self-peptide
complexes, or ERAP1-risk alleles in combination with HLA-B27 may
result in reduced mucosal immunity and increased bacterial
invasion of the gut mucosa, driving IL23 production.26 These
theories, along with recent suggestions that autophagy maybe be
critical to development of inﬂammation in AS,27 warrant further
investigation.
SUBJECTS AND METHODS
Patient groups
Forty-nine patients diagnosed with AS were included in this study and
grouped by their genotype; HLA-B27+rs30187risk (n= 14), HLA-B27+
rs30187protective (n= 28), HLA-B27−rs30187risk (n= 1) and HLA-B27−
rs30187protective (n= 6). AS was deﬁned according to the modiﬁed New
York criteria.22 Patient demographics, erythrocyte sedimentation rate,
C-reactive protein and Bath Ankylosing Spondylitis Disease Activity Index
scores are described in detail in Table 1. Thirteen of the 49 patients have
taken TNF inhibitors at the time of blood collection; all other patients had
not received TNF inhibitor therapy. No participant received corticosteroids.
Peripheral venous blood was collected from AS patients attending the
Princess Alexandra Hospital Ankylosing Spondylitis Clinic. Ethical approval
was granted by the Princess Alexandra Hospital and University of
Queensland Ethics Committees. Written informed consent from all
participants was received prior to inclusion in the study.
Terminal ileal biopsies were consecutively sampled from 21 AS patients
without clinical symptoms of bowel inﬂammation at the University of
Palermo (Italy) Ankylosing Spondylitis Clinic. Ten out of 21 AS patients have
taken non-steroidal anti-inﬂammatory drugs at the time of ileocolono-
scopy, none received DMARDs, corticosteroids or biological agents. As a
control group 10 normal subjects (7 male and 3 female patients, age
ranging from 35 to 68 years) who have undergone ileocolonscopy for
routine evaluation were also evaluated. Paired specimens for histological
analysis and qPCR were obtained. All patients and controls provided a
signed agreement for this study, and the protocol was approved by the
local Ethics Committee of the University of Palermo.
Figure 4. No correlation between ER-stress gene expression and inﬂammation in HLA-B27+ AS patients. Linear regression analyses were
performed to compare clinical measures of disease activity with levels of GRP78 (a–c) and CHOP (d–f) gene expression. No relationship was
found between ER-stress levels and clinical measures of disease activity.
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Sample preparation
PBMCs were extracted from heparinised blood using a standard density
gradient centrifugation over Ficoll-Paque Plus (GE Healthcare, Uppsala,
Sweden). RNA was extracted from isolated PBMC using TRIzol (Life
Technologies, Rockville, MA, USA) and cDNA was reverse transcribed
(Bioline, Alexandria, NSW, Australia) for qPCR analysis. Serum was collected
in serum-separating tubes and centrifuged at 3000 g for 10 min. Ileal
biopsies soon after removal were stored in RNAlater solution (Applied
Biosystems, Foster City, CA, USA). Each sample was lysed in a tissue
homogeniser and RNA was extracted using the commercially available
illustra RNAspin mini isolation kit (GE Healthcare, Little Chalfont, UK),
according to manufacturer’s instructions. Total RNA was reverse tran-
scribed to cDNA using the high capacity cDNA reverse transcription kit
(Applied Biosystems). Samples were stored at –20 °C until use.
Quantitative polymerase chain reaction
Expression of GRP78, CHOP, IL17A and TNF were assayed by SYBR Green
(Invitrogen, Carlsbad, CA, USA) qPCR assays using the primers described
in Supplementary Material. Gene expression was normalised against
expression of 60S ribosomal protein L32 (RPL32). IL23 gene expression
was assayed using a TaqMan (Applied Biosystems) pre-designed assay
and normalised against expression of glyceraldehyde 3-phosphate
dehydrogenase (GAPDH).
IFN-γ stimulation
PBMC from six HLA-B27+rs30187risk and six HLA-B27+rs30187protective
individuals were cultured in vitro in the presence or absence of 100 Uml− 1
recombinant human IFN-γ (R&D Systems, Minneapolis, MN, USA) for 24 h,
as described previously,15 prior to RNA extraction.
Enzyme-linked immunosorbent assay
TNF-α and IL17 enzyme-linked immunosorbent assay (ELISA) were
performed on serum samples using ELISA Max Deluxe ELISA kits
(BioLegend, San Diego, CA, USA). Assays were performed according to
the manufacturer’s instructions using neat serum for IL17 and 1:5 dilution
of serum in PBS for TNF-α. ELISA plates were read on FluoStar Optima
microplate ﬂuorometer (BMG Labtech, Mornington, VIC, Australia).
TaqMan SNP rs30187 genotyping
SNP rs30187 was genotyped on a ViiA 7 Fast Real-Time PCR System
Instrument by using allele-speciﬁc TaqMan MGB probes (Applied
Biosystems) labelled with ﬂuorescent dyes FAM and VIC (Applied
Biosystems, Catalogue no. 4351379), according to the manufacturer's
protocols. Allelic discrimination was made with the ViiA 7 Software v1.2.2
(Applied Biosystems). All the cases were run as triplicates to check for
genotyping errors. We studied one SNP in the ERAP1 gene, rs30187
(Lys528Arg).
Figure 5. ER-stress signature is not altered by ERAP1 in the gut of AS patients. Terminal ileal biopsies were taken from AS patients with active
disease. ERAP1 genotype (rs30187) was determined using TaqMan genotyping probes. All patients were HLA-B27+. Expression of GRP78
(a) and the ratio of spliced:unspliced XBP-1 (b) were determined by qRT–PCR. Neither the relative expression of GRP78 nor the ratio of spliced:
unspliced XBP-1 was altered by carriage of risk or protective alleles of ERAP1 rs30187. (c) Representative immunohistochemical staining for
GRP78 and XBP-1 in ileal biopsies from healthy (original magniﬁcation x250). The number of GRP78+ (d) and XBP-1+ (e) cells per section was
also unaltered by ERAP1 genotype (P40.05 in all comparisons).
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Table 1. Patient demographic and clinical details
HLA-B27 ERAP1 rs30187 Gender Age ESR CRP BASDAI Anti-TNF DMARDS
+ Risk M 35 10 o1.0 ND N NSAIDs
+ Risk M 36 39 30 5.4 N NSAIDs
+ Risk F 62 8 21 6.4 N NSAIDs
+ Risk M 41 22 14 6.1 N NSAIDs
+ Risk M 62 54 19 7.3 N —
+ Risk M 46 52 65 5.3 N NSAIDs
+ Risk M 39 28 7.4 8.6 N NSAIDs
+ Risk M 35 21 14 5.9 N NSAIDs
+ Risk M 35 7 1.2 3.8 N NSAIDs
+ Risk M 48 10 20 8.6 N Sulfasalazine, NSAIDs
+ Risk F 44 0.1 7 0.1 Y Methotrexate
+ Risk F 27 4 1.6 0.7 Y —
+ Risk M 31 2 1 5 N NSAIDs
+ Risk M 41 2 1.9 1.1 N NSAIDs
+ Risk M 33 2 1.8 1.5 Y NSAIDS
+ Protective F 59 38 19 1.7 Y —
+ Protective M 53 ND ND 1.2 N NSAIDs
+ Protective M 44 58 44 3.1 Y NSAIDs
+ Protective M 47 8 20 3.4 Y —
+ Protective M 38 3 o1.0 0.2 N NSAIDs
+ Protective M 37 4 13 2.4 Y —
+ Protective M 41 16 12 4.4 N —
+ Protective M 28 4 3 2.3 Y —
+ Protective M 59 6 8.5 2.4 Y NSAIDs
+ Protective M 47 6 o1.0 0.8 Y —
+ Protective M 37 5 4.2 6.8 N NSAIDs
+ Protective M 60 33 8 4.7 N NSAIDs
+ Protective M 31 25 11 8.6 N NSAIDs
+ Protective F 24 45 8.6 8.2 N NSAIDs
+ Protective M 45 5 o1.0 0.8 Y —
+ Protective F 38 14 3.5 4.8 N —
+ Protective M 35 13 2.9 3.2 N NSAIDs
+ Protective M 21 13 3.6 1 N —
+ Protective M 60 9 1.4 0.7 Y Sulfasalazine
+ Protective M 38 19 24 1.1 N —
+ Protective M 29 5 2.2 ND N NSAIDs
+ Protective M 26 19 21 7.8 N NSAIDs
+ Protective F 51 13 38 9.4 N NSAIDs
+ Protective M 26 19 21 7.8 N NSAIDs
+ Protective M 55 5 2.6 3.4 N NSAIDs
+ Protective M 67 52 34 5.6 N Methotrexate, sulfasalazine
+ Protective M 30 8 4.6 1.6 N Sulfasalazine, NSAIDs
+ Protective M 33 23 12 9.3 N Sulfasalazine, NSAIDs
− Risk M 61 16 29 8.8 N Sulfasalazine, NSAIDs
− Protective M 45 27 16 7.2 N NSAIDs
− Protective M 55 26 11 6.2 N Sulfasalazine, NSAIDs
− Protective M 34 o2 o1 0.9 Y —
− Protective F 52 11 1 2.9 N NSAIDs
− Protective M 37 ND ND 5.2 N Unknown
− Protective F 24 20 14 5.5 N NSAIDs
− Protective M 65 57 30 1.4 N NSAIDs
+ Protective M 35 33 12 6.8 N NSAIDs
+ Protective F 28 28 7 7 N —
+ Protective M 37 18 3 6.2 N —
+ Protective M 43 44 18 7.8 N NSAIDs
+ Protective M 40 16 1.8 5.6 N —
+ Protective M 35 8 2 4.2 N —
+ Risk M 46 18 3 4.5 N NSAIDs
+ Protective F 24 9 0.8 4.4 N NSAIDs
+ Protective F 33 26 1.2 5 N NSAIDs
+ Risk M 37 33 3 6 N —
+ Protective M 38 21 1.6 6.6 N —
+ Risk M 54 18 0.9 7 N NSAIDs
+ Protective M 47 7 0.5 6 N NSAIDs
+ protective M 22 34 12 6.7 N NSAIDs
+ Protective F 43 27 5 7 N —
+ Risk M 45 56 33 8 N —
+ Protective M 44 33 11 5.6 N —
+ Risk M 52 21 4 4.5 N —
+ Protective M 48 22 2 5 N NSAIDs
+ Protective M 33 14 0.5 6 N NSAIDs
+ Protective M 47 9 0.9 7.7 N —
Abbreviations: BASDAI, Bath Ankylosing Spondylitis Disease Activity Index scores; CRP, C-reactive protein; DMARDs, disease-modifying anti-rheumatic drugs;
ERAP1, endoplasmic reticulum aminopeptidase 1; ESR, erythrocyte sedimentation rate; F, female; HLA-B27, human leukocyte antigen B27; M, male; N, not
receiving anti-TNF; ND, not determined; NSAIDs, non-steroidal anti-inﬂammatory drugs; TNF, tumour necrosis factor; Y, receiving anti-TNF.
Disease-associated polymorphisms in ERAP1
TJ Kenna et al
7
© 2014 Macmillan Publishers Limited Genes and Immunity (2014), 1 – 8
Histology and immunohistochemistry
Specimens from patients with AS were divided into three subgroups as
previously described:28 those with normal gut histology, those with acute
inﬂammation and those with chronic inﬂammation. Brieﬂy, acute
inﬂammation was deﬁned by the presence of neutrophils and/or
eosinophils in the crypt and villus epithelium with preservation of normal
architecture. Chronic inﬂammation was deﬁned by alterations of the
mucosal architecture, with villous blunting and fusion in the ileal mucosa,
an increased mononuclear cell inﬁltrate and formation of basal lymphoid
aggregates in the lamina propria. Immunohistochemistry for XBP-1 and
HSPA5 was performed on 5-μm-thick parafﬁn-embedded sections
obtained from intestinal biopsy specimens from patients and controls,
and lymph node (used as positive controls) as previously described.27 The
primary antibodies, rabbit anti-human GRP78 (1:100 dilution; LSBio, Seattle,
WA, USA) and rabbit anti-human XBP-1 (1:100 dilution; Novus Biological,
Littleton, CO, USA) were added and incubated for 1 h at room temperature.
Ileal and lymph nodal sections incubated with an isotype-matched control
antibody were used as negative control. The number of GRP78 and XBP-1-
expressing cells was determined by counting the immunoreactive cells on
photomicrographs obtained from three random high-power microscopic
ﬁelds (original magniﬁcation x400) under a Leica DM2000 optical
microscope using a Leica DFC320 digital camera (Leica Microsystems,
North Ryde, NSW, Australia). Results were reported as the median (range).
Statistical analysis
Quantitation data from the qPCR were generated by the Rotor-Gene 1.7.75
software (Qiagen, Doncaster, VIC, Australia). All data displayed in graphs
represent the mean± s.e.m. For comparisons between multiple groups
differences were compared using the Kruskal–Wallis one-way analysis of
variance test with Dunn’s multiple comparison post-hoc test. For
comparison of two groups Mann–Whitney U-test was used to determine
the statistical signiﬁcance. Correlation between ER-stress gene expression
and clinical measures of disease activity were analysed using linear
regression. All statistical analyses were performed in GraphPad Prism 5
software (GraphPad, San Diego, CA, USA). Statistical signiﬁcance was
accepted at a signiﬁcance level of Po0.05.
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